CHMP recommends EU approval of Roche ’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC

Roche announced today that the European Union ’s (EU) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Alecensa® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCL C).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news